M-TOR inhibitors in the treatment of advanced renal cell carcinoma

Rafał Stec; Michał Mączewski; Marta Smoter; Lubomir Bodnar; Cezary Szczylik

doi:10.5114/wo.2011.26432

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2011
vol. 15

Send email

Copy url:

abstract:

Review paper

M-TOR inhibitors in the treatment of advanced renal cell carcinoma

Rafał Stec

,

Michał Mączewski

,

Marta Smoter

,

Lubomir Bodnar

,

Cezary Szczylik

Wspolczesna Onkol 2011; 15 (6): 343–349

DOI: https://doi.org/10.5114/wo.2011.26432

Online publish date: 2011/12/28

View full text Get citation

PlumX metrics:

Renal cell cancer (RCC) accounts for approximately 3% of all registered malignancies in Poland. According to the most recent National Cancer Register, 2283 men and 1483 women were diagnosed with renal cancer in 2006. Up to 30% of patients with RCC present with metastatic disease. M-TOR inhibitors became a new therapeutic option for patients with metastatic RCC. Two of them, temsirolimus and everolimus, are currently approved for clinical use for patients with advanced renal cancer. Anticancer activity of m-TOR inhibitors is related to cellular cycle regulation and inhibition of uncontrolled angiogenesis. Based on clinical trials, temsirolimus is indicated as the first line of chemotherapy for patients with at least three poor prognostic factors. Everolimus should be administered as the second line of treatment, for patients who relapsed after antiangiogenic therapy.

keywords:

M-TOR inhibitors in the treatment of advanced renal cell carcinoma

Rafał Stec , Michał Mączewski , Marta Smoter , Lubomir Bodnar , Cezary Szczylik

renal cancer, m-TOR inhi­bitors, temsirolimus, everolimus

Rafał Stec

,

Michał Mączewski

,

Marta Smoter

,

Lubomir Bodnar

,

Cezary Szczylik

renal cancer, m-TOR inhibitors, temsirolimus, everolimus